List of Excipients in Branded Drug PROCYSBI

« Back to Dashboard

Procysbi Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Procysbi is a delayed-release cysteamine bitartrate product for the treatment of nephropathic cystinosis. Its commercial value depends on more than the active ingredient. The product’s excipient system supports enteric protection, odor reduction, gastrointestinal tolerability, dose flexibility, and differentiation from immediate-release cysteamine products.

The main commercial opportunity is in excipient technologies that preserve cysteamine during gastric transit while enabling reliable intestinal release. Opportunities also exist in pediatric formulations, sprinkle administration, taste and odor control, generic development, regional supply, and formulation licensing.

What is Procysbi and how does its formulation work?

Procysbi contains cysteamine bitartrate in delayed-release oral dosage forms. The product is marketed as delayed-release capsules and oral granules for patients who cannot reliably swallow capsules or require administration with soft food or liquid. The product is approved under FDA NDA 203389. Horizon Therapeutics commercialized Procysbi before its acquisition by Amgen in 2023. [1,2]

Cysteamine has a strong sulfur odor and can cause gastrointestinal adverse effects. Immediate-release cysteamine products require frequent administration. Procysbi uses enteric-coated, delayed-release technology to move release away from the stomach and reduce dosing frequency. The FDA-approved labeling instructs patients to take Procysbi every 12 hours. [1]

Product attribute	Procysbi commercial strategy
Active ingredient	Cysteamine bitartrate
Therapeutic area	Nephropathic cystinosis
Dosage forms	Delayed-release capsules and oral granules
Administration	Every 12 hours
Key formulation objective	Delayed intestinal release
Main patient issue addressed	Odor, gastrointestinal tolerability, and dosing burden
Primary commercial differentiator	Delayed-release cysteamine delivery
FDA application	NDA 203389
Current commercial owner	Amgen, following acquisition of Horizon Therapeutics

What excipients are used in Procysbi?

Procysbi uses a multiparticulate delayed-release formulation. The excipient strategy includes core-forming materials, protective or enteric polymers, processing aids, and capsule or granule presentation components. The FDA prescribing information identifies inactive ingredients for the approved dosage forms. [1]

The relevant excipient functions are:

Excipient category	Function in Procysbi
Microcrystalline cellulose	Pellet or core matrix and mechanical support
Croscarmellose sodium	Disintegration and release support
Magnesium stearate	Lubrication during manufacture
Colloidal silicon dioxide	Flow and powder-processing control
Talc	Coating or processing aid
Hypromellose	Film-forming and coating support
Methacrylic acid copolymer	Enteric protection and pH-dependent release
Triethyl citrate	Plasticizer for polymer coatings
Capsule-shell materials	Dose presentation, identification, and handling

The precise qualitative and quantitative composition, coating weight gain, particle-size distribution, and manufacturing parameters are commercially important. Two products may contain the same active ingredient and broadly similar excipients but show different dissolution, stability, odor, or gastrointestinal performance because of differences in pellet structure and coating process.

Why methacrylic acid copolymer matters

Methacrylic acid copolymers are commonly used as enteric polymers. They remain relatively intact at low gastric pH and dissolve at higher intestinal pH. In Procysbi, the polymer coating is central to the delayed-release profile.

Commercially relevant variables include:

• Polymer grade and acid-to-ester ratio
• Coating weight gain
• Plasticizer concentration
• Spray rate and inlet temperature
• Pellet porosity
• Film thickness uniformity
• Residual solvent or moisture
• Mechanical resistance during capsule filling
• Dissolution performance across gastric and intestinal pH stages

These parameters can create process and formulation barriers even where the active ingredient is off patent.

What excipient technologies protect cysteamine from degradation?

Cysteamine is chemically reactive and sensitive to formulation conditions. Excipient selection must control moisture, oxygen exposure, pH microenvironment, and contact with reactive packaging materials.

Moisture control

Moisture can affect cysteamine stability, polymer performance, pellet strength, and capsule-shell behavior. Commercial controls may include:

• Low-moisture excipients
• Tight water-activity specifications
• Desiccant packaging
• High-barrier bottles or blister systems
• Controlled-humidity coating and filling operations
• Moisture-resistant secondary packaging

A generic manufacturer may reproduce the listed excipients but still face stability differences if its water activity, coating porosity, or packaging system differs.

Odor management

Cysteamine’s sulfur odor is a major patient and caregiver concern. Excipient and packaging approaches can include:

• Delayed release that reduces upper gastrointestinal exposure
• Film coatings that limit odor release before administration
• Odor-barrier packaging
• Low-headspace containers
• Unit-dose packaging
• Flavor or taste-masking systems for granules
• Co-administration instructions using approved food vehicles

Odor control is commercially valuable, but a formulation cannot compromise dissolution, bioavailability, or the product’s labeled administration conditions.

Gastric protection

Enteric polymers provide the primary protection against premature release. The formulation must tolerate the acidic stomach environment and release predictably in the intestine. Relevant development tests include:

• Acid-stage dissolution
• Buffer-stage dissolution
• Delayed-release onset
• Dose proportionality
• Food-effect assessment
• Stability after opening
• Compatibility with soft food or liquid administration

What formulation patents protect Procysbi?

The core intellectual-property strategy for Procysbi is likely concentrated in delayed-release cysteamine formulations, multiparticulate dosage forms, dosing regimens, and methods of treating cystinosis. The formulation itself is more commercially defensible when the claims cover a combination of:

1. Cysteamine or cysteamine bitartrate particles.
2. A delayed-release or enteric coating.
3. Specific release behavior across pH conditions.
4. Twice-daily administration.
5. Reduced dosing frequency compared with immediate-release cysteamine.
6. Administration of capsules or granules.
7. Stability, odor reduction, or gastrointestinal tolerability.

The FDA Orange Book should be reviewed for the patents listed against NDA 203389, including patent numbers, use codes, and expiration dates. Orange Book listings can determine whether an abbreviated new drug application requires a Paragraph IV certification or a section viii statement. [3]

A complete patent assessment should separate:

Patent category	Commercial relevance
Composition patents	Protect cysteamine-containing delayed-release particles or formulations
Formulation patents	Protect coating systems, excipient ratios, and release profiles
Method-of-use patents	Protect twice-daily dosing or cystinosis treatment methods
Manufacturing patents	Protect pellet formation, coating, drying, or packaging
Stability patents	Protect moisture, odor, or shelf-life performance
Regulatory patents	Listed in the Orange Book and relevant to ANDA certification

Excipient patents generally have less value when they claim only routine use of a known enteric polymer. Their value increases when the claims link the excipient system to a non-obvious release profile, improved stability, reduced adverse effects, or a clinically meaningful dosing advantage.

When does Procysbi lose exclusivity?

Procysbi’s market exclusivity has multiple components:

• FDA orphan-drug exclusivity
• Listed patents
• Potential formulation and method-of-use claims
• Regulatory exclusivity associated with the original approval
• Trade secrets covering coating, pelletization, and quality-control parameters

Procysbi received approval for a rare disease indication, making orphan-drug exclusivity commercially relevant. Orphan exclusivity generally blocks FDA approval of the same drug for the same indication for seven years from approval, subject to statutory exceptions. Patent expiration may occur later or earlier than regulatory exclusivity. [1,4]

The practical generic-entry date depends on:

• The earliest enforceable patent expiration
• Any pediatric exclusivity extension
• Whether an ANDA applicant files a Paragraph IV certification
• The timing of patent litigation
• The scope of listed use codes
• Whether the applicant pursues capsules, granules, or both

The Orange Book, FDA approval history, and court docket should be used together. Patent expiration cannot be inferred from the date of FDA approval alone.

What generic entry risks exist for Procysbi?

Procysbi has a higher development burden than a conventional immediate-release capsule. A competing ANDA must address delayed-release performance, product strength, particle size, coating integrity, stability, and administration instructions.

Paragraph IV risk

A generic applicant could challenge listed patents through a Paragraph IV certification. Potential invalidity or non-infringement positions may target:

• Obviousness of using known enteric polymers
• Lack of written description for broad excipient claims
• Failure to distinguish prior cysteamine formulations
• Non-infringement based on different coating composition
• Non-infringement based on different release thresholds
• Patent claims directed only to a particular use code

The reference-product sponsor could respond with patent litigation under the Hatch-Waxman framework. A timely suit can trigger a statutory stay of FDA approval, generally up to 30 months, subject to statutory exceptions and court decisions. [5]

Formulation substitution risk

Even if a generic product receives approval, automatic substitution may depend on dosage form, therapeutic equivalence, state law, and payer policy. A product with different administration instructions or a materially different granule presentation may have a weaker substitution position.

Manufacturing risk

The main manufacturing barriers are likely to include:

• Uniform coating of small multiparticulates
• Reproducible enteric dissolution
• Low-moisture processing
• Control of odor during filling
• Pellet attrition
• Capsule-fill weight variation
• Long-term stability
• Compatibility with high-barrier packaging

These are practical barriers rather than absolute legal barriers. A contract development and manufacturing organization with fluid-bed coating and multiparticulate experience could reduce development time.

What commercial opportunities exist in Procysbi excipients?

Excipient-supplier opportunities

Excipient suppliers can target:

• Enteric polymers with tighter particle-size specifications
• Low-moisture microcrystalline cellulose
• Improved plasticizers for flexible enteric films
• Odor-barrier coating systems
• Direct-compression or pelletization aids
• High-barrier packaging materials
• Desiccant-integrated containers
• Taste-masking systems for pediatric granules

The strongest value proposition is not a generic excipient replacement. It is a qualified platform that improves dissolution consistency, shelf life, odor control, or manufacturing yield without changing the clinical performance of the product.

Pediatric formulation opportunities

Nephropathic cystinosis is a lifelong disease that often requires treatment from childhood. Pediatric-friendly improvements can include:

• Smaller granule size
• Reduced swallowing burden
• Better taste and odor masking
• Single-dose sachets
• Unit-dose packaging
• Easier dose titration
• Improved compatibility with labeled soft foods
• Lower risk of dosing errors

A pediatric formulation must preserve the product’s delayed-release behavior. Taste masking that causes premature release would undermine the product’s core function.

Lifecycle-management opportunities

Potential lifecycle products include:

Opportunity	Commercial rationale
Improved granules	Supports younger children and patients unable to swallow capsules
Unit-dose sachets	Improves portability and adherence
Lower-odor presentation	Addresses a major patient complaint
More robust packaging	Reduces stability risk after opening
Simplified titration	Supports individualized cysteamine dosing
New regional manufacturing	Reduces supply-chain dependence
Combination adherence tools	Links dosing to cysteamine monitoring and disease management

A new formulation may require a separate FDA application or supplement, depending on the degree of change and the applicable regulatory pathway. Excipient changes that affect release, stability, or bioavailability can trigger substantial comparative testing.

How does Procysbi compare with immediate-release cysteamine?

Attribute	Procysbi	Immediate-release cysteamine
Release profile	Delayed release	Immediate release
Dosing frequency	Every 12 hours under labeling	More frequent dosing
Main excipient challenge	Enteric protection and controlled release	Stability, odor, and tolerability
Manufacturing complexity	High multiparticulate-coating burden	Generally lower
Pediatric flexibility	Capsules and granules	Product-dependent
Generic development	Requires complex release matching	More conventional
Commercial differentiation	Dosing convenience and delayed release	Lower formulation complexity and potential cost

Procysbi’s excipient strategy supports a premium product position. A generic competitor could have a lower cost base but would need to reproduce the delayed-release performance and address the same patient-use requirements.

What is the FDA and Orange Book status of Procysbi?

Procysbi is an FDA-approved prescription product under NDA 203389 for nephropathic cystinosis. FDA labeling identifies the delayed-release capsule and granule presentations and provides administration, dosing, and inactive-ingredient information. [1]

The Orange Book is the controlling public source for current listed patents, use codes, therapeutic-equivalence evaluations, and patent certifications associated with the NDA. Patent status should be assessed against the current Orange Book entry rather than relying on historical patent summaries. [3]

Key Takeaways

• Procysbi’s primary formulation value is its delayed-release cysteamine delivery system.
• Methacrylic acid copolymer, hypromellose, triethyl citrate, and processing excipients support enteric protection and manufacturability.
• Moisture control, odor reduction, pediatric administration, and packaging are major commercial opportunities.
• Generic entry faces multiparticulate coating, dissolution, stability, and administration challenges.
• The strongest excipient opportunities involve qualified improvements tied to release, stability, odor, or manufacturing yield.
• Orange Book patents, FDA labeling, and litigation records must be reviewed together to determine the practical exclusivity position.
• Pediatric granules, unit-dose packaging, and improved odor control are the most commercially credible lifecycle strategies.

FAQs

Can Procysbi be reformulated with different enteric polymers?

Yes, but the alternative formulation would need to demonstrate comparable delayed-release performance, stability, and clinical or bioequivalence characteristics under the applicable FDA pathway.

Are Procysbi excipients themselves likely to block generic approval?

Routine excipients are unlikely to create meaningful protection by themselves. Patent value depends on claimed combinations, coating parameters, release behavior, and therapeutic use.

Is cysteamine bitartrate difficult to manufacture?

The active ingredient is less commercially difficult than the finished delayed-release product. Multiparticulate coating, odor control, moisture management, and dissolution consistency create the larger manufacturing burden.

Can Procysbi granules support a pediatric product strategy?

Yes. Granules provide a route for patients who cannot swallow capsules. The main development issues are taste, odor, dosing accuracy, food compatibility, and maintenance of enteric release.

What is the most attractive commercial opportunity around Procysbi?

A pediatric, low-odor, unit-dose delayed-release presentation is the strongest opportunity because it addresses adherence and administration problems while preserving the product’s core formulation advantage.

References

1. U.S. Food and Drug Administration. (2024). Procysbi (cysteamine bitartrate) delayed-release capsules and oral granules: Prescribing information.
2. Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content, format, and review procedures.